Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00605176 · ClinicalTrials.gov registry record · Phase 3
Safety and Effectiveness Study of Imiquimod Creams for Treatment of Actinic Keratoses (AKs)
A Phase 3 study, sponsored by Graceway Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 479
- Enrollment target
NCT00605176 is a Phase 3 study that has completed, run by Graceway Pharmaceuticals. The registered enrollment target is 479 participants.
The verdict
NCT00605176, a Phase 3 study, has completed, sponsored by Graceway Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 479 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether imiquimod creams are effective in treating Actinic Keratoses when applied to the face or balding scalp. Actinic keratosis (AK) is a skin condition that shows up on skin routinely exposed to the sun, such as the face, scalp, shoulders, chest, back, arms, and hands. The active ingredient contained in the study cream for this study is the same as that of the approved product Aldara, which has been shown to be safe and effective for the treatment of AKs.
Interventions
- DRUG Placebo
- DRUG imiquimod cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 479 participants |
| Start Date | 2008-01 |
| Est. Completion | 2008-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00605176
The ClinicalTrials.gov registry entry for NCT00605176 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 479 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Graceway Pharmaceuticals, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00605176 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00605176 about?
NCT00605176 is a clinical study titled "Safety and Effectiveness Study of Imiquimod Creams for Treatment of Actinic Keratoses (AKs)". The purpose of this study is to determine whether imiquimod creams are effective in treating Actinic Keratoses when applied to the face or balding scalp. Actinic keratosis (AK) is a skin condition that shows up on skin routinely exposed to the sun, such as the face, scalp, shoulders, chest, back, a...
What is the current status of trial NCT00605176?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 479 participants. The study started on 2008-01. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00605176?
The interventions under investigation include: Placebo (DRUG), imiquimod cream (DRUG).
Who is sponsoring clinical trial NCT00605176?
This trial is sponsored by Graceway Pharmaceuticals, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.